Related Experiment Video
Updated: Sep 6, 2025
08:26
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
Published on: February 23, 2024
2.1K
Practical Strategies for Advanced Practitioners Streamlining the Integration of Oncology Biosimilar Therapies Into
Kelley D Mayden1, John M Kelton2, Joanne C Ryan2
1Ballad Health Cancer Care, Bristol, Virginia.
Journal of the Advanced Practitioner in Oncology
|June 27, 2022
Summary
Biosimilars offer affordable cancer treatment options. Advanced practitioners play a key role in integrating these highly similar biological medicines into oncology practices, requiring knowledge and confidence-building strategies.
Area of Science:
- Oncology
- Pharmacology
- Health Services Research
Background:
- Biosimilars are emerging as cost-effective alternatives to reference biologics in US oncology.
- Advanced practitioners (APs) are increasingly involved in introducing monoclonal antibody (mAb) biosimilars.
- Patient and colleague confidence in biosimilars requires APs to be well-informed.
Purpose of the Study:
- To review the practical aspects of integrating biosimilar therapies into oncology settings.
- To equip advanced practitioners with knowledge for effective biosimilar implementation.
- To address challenges associated with introducing biosimilar monoclonal antibodies.
Main Methods:
- Literature review on biosimilar development and regulatory approval.
- Analysis of the role of advanced practitioners in clinical practice.
- Discussion of strategies for overcoming barriers to biosimilar adoption.
Main Results:
- Biosimilarity requires rigorous comparison for efficacy, safety, and tolerability.
- APs face challenges in building trust and familiarity with biosimilars.
- Successful integration necessitates comprehensive understanding and strategic implementation.
Conclusions:
- Advanced practitioners are pivotal in the adoption of biosimilar monoclonal antibodies.
- Streamlining biosimilar integration requires addressing knowledge gaps and fostering confidence.
- Biosimilars represent a sustainable approach to cancer treatment, enhancing accessibility.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:27Tumor Immunotherapy
652
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:16Bioequivalence: Overview
1.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.2K